🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond

Recruitingn/aAges 18 Years - anyAllArbeitsgemeinschaft medikamentoese Tumortherapie
NCT06678919 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * patients ≥ 18 years with tissue-based diagnosis of mCRC * ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.) Exclusion Criteria: * Due to the non-interventional design of this registry, there are no specific exclusion criteria
💊

What it tests

  • Not listed
📍

Where

7 sites
Ordensklinikum Linz, BHS - Interne I
Linz, Austria
KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische Onkologie
Linz, Austria
LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie)
Rankweil, Austria
Department of Internal Medicine III, Paracelsus Medical University Salzburg
Salzburg, Austria
Klinikum Steyr: Innere Medizin II: Onkologie, Gastroenterologie, Angiologie
Steyr, Austria
Klinikum Wels: Abteilung für Innere Medizin IV
Wels, Austria
KH Zams: Innere Medizin Internistische Onkologie und Hämatologie
Zams, Austria
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy